When was Aprea founded?

Aprea was founded in 2003 and raised its 1st funding round 13 years after it was founded.

Where is Aprea located?

Aprea is headquartered in Boston, United States.

How many employees does Aprea have?

As of Aug 31, 2026, the latest employee count at Aprea is 6.

Is Aprea a funded company?

Aprea is a funded company, having raised a total of $113M across 6 funding rounds to date. The company's 1st funding round was a $***** Series B round, raised on Mar 09, 2016.

When was the latest funding round of Aprea?

Aprea's latest funding was a $***** Post IPO round on Dec 09, 2025, with participation from 0 investor. Its primary sector is Oncology. In United States, the Oncology sector has seen $3.95B in funding in 2026 to date.

Where does Aprea rank among its competitors?

Aprea ranks 94th amongst 3349 active competitors, of which 1124 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Aprea?

Aprea's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Aprea - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Developer of small molecule therapeutics targeting tumor suppressor proteins. The company focuses on p53, a tumor suppressor protein that induces cell cycle arrest or cell death. The company's lead candidate is APR-246, that acts by reactivating mutant and defective native p53, leading to tumor cell death. The company is also developing APR-017, which induces p53-mediated apoptosis by restoring p53 activity in cancer cell lines with mutant p53.

Key Metrics

Founded Year

2003

Location

Boston, United States

Stage

Public

Total Funding

$113M in 6 rounds

Latest Funding Round

Post IPO, Dec 09, 2025, $*****

Investors

Janus Henderson Investors & 16 more

Ranked

94^th among 3349 active competitors

Employee Count

6 as on Aug 31, 2026

Investment & Acquisitions

Atrin Pharma

Similar Companies

Jazz Pharmaceuticals & 2998 more

Exit Details

Public

View Aprea's full profile

Aprea is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
APREA THERAPEUTICS, INC. CIN: 1781983 , United States, Active	May 02, 2019	-	8 (As on Dec 31, 2021)	-
APREA & MICHELI, INC. CIN: 943316325 , United States, Active	May 02, 2019	-	2 (As on Dec 31, 2024)	-

Aprea got listed on Oct 03, 2019.

Click here to take a look at Aprea's IPO in detail

Aprea has raised a total funding of $113M over 6 rounds. Its first funding round was on Mar 09, 2016. Aprea has 17 institutional investors.

Here is the list of recent funding rounds of Aprea:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 09, 2025	3101350	Post IPO	3624945	6494579	1560037	4744016
Mar 11, 2024	1204568	Post IPO	9474277	6305624	5996984	Nantahala Capital Management & 4 more
Feb 10, 2023	1130900	Grant (prize money)	4329847	5053654	2206242	HHS

Access funding benchmarks and valuations. Sign up today!

View details of Aprea's funding rounds and investors

Aprea's employee count trend

Aprea has 6 employees as of Aug 26. Here is Aprea's employee count trend over the years:

Uncover Aprea's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Aprea include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Aprea, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
94th	Aprea 2003, Boston (United States), Public	Developer of small molecule therapeutics targeting tumor suppressor proteins	$113M	ADS Ventures, Janus Henderson Investors & 15 others	63/100